|1.||Dixon, R M: 1 article (06/2000)|
|2.||Littlewood, T J: 1 article (06/2000)|
|3.||Thompson, C H: 1 article (06/2000)|
|4.||Rajagopalan, B: 1 article (06/2000)|
|5.||O'Byrne, K: 1 article (06/2000)|
|6.||Harris, A L: 1 article (06/2000)|
|7.||Braybrooke, J P: 1 article (06/2000)|
|8.||Talbot, D C: 1 article (06/2000)|
|9.||Propper, D J: 1 article (06/2000)|
|10.||Ganesan, T S: 1 article (06/2000)|
05/01/1989 - "86Rb extraction studies on BW12C-treated unheated animals showed that blood flow in leg and flank tumours 60 min after BW12C was reduced to 64% and 34% of control values respectively, indicating a further mechanism for induction of tumour hypoxia by BW12C. "
10/01/1991 - "The data as a whole indicate that reduction in tumour perfusion is likely to be an important determinant in the increase in tumour hypoxia induced by BW12C."
10/01/1991 - "BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice."
06/01/2000 - "BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) stabilizes oxyhaemoglobin, causing a reversible left-shift of the oxygen saturation curve (OSC) and tissue hypoxia. "
08/01/1994 - "BW12C is a drug that has the potential to induce normal tissue and tumour hypoxia by binding to haemoglobin, increasing its affinity for oxygen and thereby reducing oxygen availability to tissues. "
|2.||Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/01/1993 - "Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer."
01/01/1992 - "Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer."
01/01/1993 - "The effect of combining the oxygen-transport-modifying drug BW12C with mitomycin C was investigated in a phase 1 study of 26 patients with advanced gastrointestinal cancer. "
01/01/1992 - "The effect of combining the oxyhemoglobin-modifying drug BW12C with mitomycin C was investigated in a Phase I study of 18 patients with advanced gastrointestinal cancer. "
|3.||Sickle Cell Anemia (Hemoglobin S Disease)
11/01/1983 - "Venous blood from patients with sickle-cell disease in the steady state or in crisis was progressively deoxygenated in vitro to study the effect of BW12C, a new compound designed to stabilize haemoglobin in the oxy-conformation, on the deformability (filterability) of washed erythrocytes. "
04/12/1986 - "Eight subjects with sickle-cell disease in the symptom-free steady-state received a single one-hour infusion of the new anti-sickling agent BW12C on a total of eleven occasions. "
04/12/1986 - "Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease."
|4.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2000 - "However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen. "
06/01/2000 - "In this phase II study, 17 patients with metastatic colorectal cancer resistant to 5-fluorouracil (5-FU) received BW12C and MMC. "
06/01/2000 - "Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer."
|5.||Pathologic Constriction (Stenosis)